vs
Side-by-side financial comparison of Identiv, Inc. (INVE) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Identiv, Inc. is the larger business by last-quarter revenue ($6.2M vs $5.5M, roughly 1.1× Taysha Gene Therapies, Inc.). Identiv, Inc. runs the higher net margin — -60.3% vs -507.8%, a 447.4% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -7.9%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -3.8%).
Identiv is a publicly traded Internet of Things technology company listed on the Nasdaq stock market.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
INVE vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.2M | $5.5M |
| Net Profit | $-3.7M | $-27.9M |
| Gross Margin | 18.1% | — |
| Operating Margin | -76.4% | -516.0% |
| Net Margin | -60.3% | -507.8% |
| Revenue YoY | -7.9% | 171.3% |
| Net Profit YoY | -948.2% | -48.3% |
| EPS (diluted) | $-0.17 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.2M | $5.5M | ||
| Q3 25 | $5.0M | $0 | ||
| Q2 25 | $5.0M | $2.0M | ||
| Q1 25 | $5.3M | $2.3M | ||
| Q4 24 | $6.7M | $2.0M | ||
| Q3 24 | $6.5M | $1.8M | ||
| Q2 24 | $6.7M | $1.1M | ||
| Q1 24 | $6.7M | $3.4M |
| Q4 25 | $-3.7M | $-27.9M | ||
| Q3 25 | $-3.5M | $-32.7M | ||
| Q2 25 | $-6.0M | $-26.9M | ||
| Q1 25 | $-4.8M | $-21.5M | ||
| Q4 24 | $-355.0K | $-18.8M | ||
| Q3 24 | $85.9M | $-25.5M | ||
| Q2 24 | $-6.2M | $-20.9M | ||
| Q1 24 | $-4.6M | $-24.1M |
| Q4 25 | 18.1% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | -9.4% | — | ||
| Q1 25 | 2.5% | — | ||
| Q4 24 | -14.9% | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 9.1% | — | ||
| Q1 24 | 7.3% | — |
| Q4 25 | -76.4% | -516.0% | ||
| Q3 25 | -111.4% | — | ||
| Q2 25 | -126.7% | -1347.1% | ||
| Q1 25 | -103.8% | -930.5% | ||
| Q4 24 | -98.9% | -985.8% | ||
| Q3 24 | -146.2% | -1448.4% | ||
| Q2 24 | -99.7% | -1915.4% | ||
| Q1 24 | -76.0% | -713.3% |
| Q4 25 | -60.3% | -507.8% | ||
| Q3 25 | -68.9% | — | ||
| Q2 25 | -119.9% | -1353.6% | ||
| Q1 25 | -90.9% | -935.2% | ||
| Q4 24 | -5.3% | -929.0% | ||
| Q3 24 | 1315.8% | -1427.5% | ||
| Q2 24 | -92.2% | -1882.0% | ||
| Q1 24 | -68.5% | -705.4% |
| Q4 25 | $-0.17 | $-0.08 | ||
| Q3 25 | $-0.15 | $-0.09 | ||
| Q2 25 | $-0.26 | $-0.09 | ||
| Q1 25 | $-0.21 | $-0.08 | ||
| Q4 24 | $0.00 | $-0.07 | ||
| Q3 24 | $3.62 | $-0.10 | ||
| Q2 24 | $-0.27 | $-0.09 | ||
| Q1 24 | $-0.21 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.6M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $140.7M | $246.9M |
| Total Assets | $151.3M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.6M | $319.8M | ||
| Q3 25 | $126.3M | $297.3M | ||
| Q2 25 | $129.3M | $312.8M | ||
| Q1 25 | $132.4M | $116.6M | ||
| Q4 24 | $135.6M | $139.0M | ||
| Q3 24 | $145.4M | $157.7M | ||
| Q2 24 | $18.4M | $172.7M | ||
| Q1 24 | $21.6M | $124.0M |
| Q4 25 | $140.7M | $246.9M | ||
| Q3 25 | $143.7M | $219.0M | ||
| Q2 25 | $146.4M | $248.7M | ||
| Q1 25 | $150.5M | $55.1M | ||
| Q4 24 | $154.1M | $71.5M | ||
| Q3 24 | $156.7M | $88.8M | ||
| Q2 24 | $65.1M | $108.9M | ||
| Q1 24 | $70.2M | $53.8M |
| Q4 25 | $151.3M | $343.3M | ||
| Q3 25 | $151.0M | $316.6M | ||
| Q2 25 | $153.9M | $333.3M | ||
| Q1 25 | $158.7M | $138.4M | ||
| Q4 24 | $163.2M | $160.4M | ||
| Q3 24 | $177.0M | $180.2M | ||
| Q2 24 | $97.8M | $200.4M | ||
| Q1 24 | $101.8M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.0M | $-26.7M |
| Free Cash FlowOCF − Capex | $2.8M | — |
| FCF MarginFCF / Revenue | 45.8% | — |
| Capex IntensityCapex / Revenue | 3.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-7.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $-26.7M | ||
| Q3 25 | $-2.9M | $-24.2M | ||
| Q2 25 | $-3.6M | $-20.2M | ||
| Q1 25 | $-3.3M | $-22.0M | ||
| Q4 24 | $-5.9M | $-18.3M | ||
| Q3 24 | $-7.2M | $-21.6M | ||
| Q2 24 | $-993.0K | $-21.5M | ||
| Q1 24 | $-1.3M | $-19.8M |
| Q4 25 | $2.8M | — | ||
| Q3 25 | $-3.2M | $-24.3M | ||
| Q2 25 | $-3.8M | — | ||
| Q1 25 | $-3.6M | — | ||
| Q4 24 | $-6.5M | $-18.3M | ||
| Q3 24 | $-7.7M | $-21.6M | ||
| Q2 24 | $-1.1M | $-21.7M | ||
| Q1 24 | $-1.5M | $-19.9M |
| Q4 25 | 45.8% | — | ||
| Q3 25 | -64.5% | — | ||
| Q2 25 | -75.8% | — | ||
| Q1 25 | -68.0% | — | ||
| Q4 24 | -97.7% | -905.5% | ||
| Q3 24 | -118.2% | -1210.9% | ||
| Q2 24 | -16.7% | -1951.9% | ||
| Q1 24 | -23.0% | -584.5% |
| Q4 25 | 3.3% | — | ||
| Q3 25 | 7.0% | — | ||
| Q2 25 | 5.0% | — | ||
| Q1 25 | 5.7% | — | ||
| Q4 24 | 9.3% | 0.1% | ||
| Q3 24 | 7.7% | 2.0% | ||
| Q2 24 | 2.0% | 18.1% | ||
| Q1 24 | 3.5% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.08× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INVE
| Other | $3.4M | 55% |
| Europe And Middle East | $2.2M | 36% |
| Asia Pacific | $575.0K | 9% |
TSHA
Segment breakdown not available.
